Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.77 EUR
Change Today +0.125 / 2.22%
Volume 0.0
As of 10:45 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

resmed inc-cdi (RMEA) Snapshot

Open
€5.77
Previous Close
€5.64
Day High
€5.77
Day Low
€5.72
52 Week High
04/13/15 - €6.99
52 Week Low
08/1/14 - €3.50
Market Cap
8.0B
Average Volume 10 Days
603.3
EPS TTM
--
Shares Outstanding
1.4B
EX-Date
05/19/15
P/E TM
--
Dividend
€0.11
Dividend Yield
1.49%
Current Stock Chart for RESMED INC-CDI (RMEA)

resmed inc-cdi (RMEA) Related Businessweek News

No Related Businessweek News Found

resmed inc-cdi (RMEA) Details

ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and management of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio includes airflow generators, diagnostic products, mask systems, motors, and headgear, as well as other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages. The company also offers data communications and control products, including EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules that facilitate the transfer of data and other information to and from the flow generators. ResMed Inc. markets its products to sleep clinics, home healthcare dealers, and third-party payers. The company sells its products through a network of distributors and direct sales force in approximately 100 countries worldwide. It has a collaboration agreement with Qualcomm Life, Inc. to develop connected health solutions based on 2net and HealthyCircles platforms. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

4,100 Employees
Last Reported Date: 08/8/14
Founded in 1989

resmed inc-cdi (RMEA) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $787.5K
President and Chief Operating Officer
Total Annual Compensation: $664.6K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $494.7K
President of Americas
Total Annual Compensation: $434.6K
Chief Administrative Officer and Global Gener...
Total Annual Compensation: $485.7K
Compensation as of Fiscal Year 2014.

resmed inc-cdi (RMEA) Key Developments

ResMed Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Gross Margin Outlook for Fourth Quarter of 2015; Provides Tax Rate Outlook for the Full Year 2015

ResMed Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company’s net revenue was $422,497,000 against $397,758,000 a year ago. Income from operations was $105,868,000 against $104,698,000 a year ago. Income before income tax was $114,358,000 against $112,912,000 a year ago. Net income was $90,983,000 against $89,969,000 a year ago. Diluted earnings per share were $0.64 against $0.63 a year ago. Non-GAAP operating income (excluding the impact of amortization of acquired intangible assets) was $108,071,000 against $107,157,000 a year ago. Non-GAAP net income (excluding the impact of amortization of acquired intangible assets) was $92,626,000 against $91,837,000 a year ago. Non-GAAP diluted earnings per share (excluding the impact of amortization of acquired intangible assets) were $0.65 against $0.64 a year ago. Cash flow from operations was $90.9 million for the quarter, reflecting strong underlying earnings and a modestly increasing working capital. Capital expenditure for the quarter was $10.6 million while depreciation and amortization for the March quarter totaled $17.9 million. For the nine months, the company’s net revenue was $1,225,848,000 against $1,139,762,000 a year ago. Income from operations was $309,689,000 against $306,601,000 a year ago. Income before income tax was $331,800,000 against $324,443,000 a year ago. Net income was $265,424,000 against $257,535,000 a year ago. Diluted earnings per share were $1.86 against $1.78 a year ago. Net cash provided by operating activities was $283,479,000 against $275,685,000 a year ago. Purchases of property, plant and equipment was $50,266,000 against $54,210,000 a year ago. Non-GAAP operating income (excluding the impact of amortization of acquired intangible assets) was $316,247,000 against $313,926,000 a year ago. Non-GAAP net income (excluding the impact of amortization of acquired intangible assets) was $270,375,000 against $263,098,000 a year ago. Non-GAAP diluted earnings per share (excluding the impact of amortization of acquired intangible assets) were $1.90 against $1.82 a year ago. Patent registration costs were $7,109,000 against $5,691,000 a year ago. For the fourth quarter of 2015, the company expects gross margin to be broadly consistent with third quarter being in the range of 59% to 60%, assuming current exchange rates. Gross margin drivers like currency fluctuations and geographic and product mix could swing this range further if they move beyond their expectations. The company estimates its effective tax rate for the full fiscal year 2015 will be in the range of 20% to 21%.

ResMed Inc. Declares Quarterly Dividend, Payable on June 18, 2015

The ResMed board of directors declared a quarterly dividend of $0.28 per share. The dividend will have a record date of May 21, 2015, payable on June 18, 2015. The ex-dividend date will be May 19, 2015 for common stock holders and for CDI holders.

ResMed Inc. to Report Q3, 2015 Results on Apr 23, 2015

ResMed Inc. announced that they will report Q3, 2015 results at 1:30 PM, Pacific Standard Time on Apr 23, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RMEA:GR €5.77 EUR +0.125

RMEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hologic Inc $34.40 USD +0.39
IDEXX Laboratories Inc $130.52 USD -2.41
Mettler-Toledo International Inc $324.04 USD +3.54
Teleflex Inc $124.61 USD +2.00
Cooper Cos Inc/The $179.08 USD +1.08
View Industry Companies
 

Industry Analysis

RMEA

Industry Average

Valuation RMEA Industry Range
Price/Earnings 26.2x
Price/Sales 5.6x
Price/Book 5.9x
Price/Cash Flow 25.2x
TEV/Sales 4.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESMED INC-CDI, please visit www.resmed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.